DiaMedica Announces Non-Brokered Private Placement

Biotech Investing

DiaMedica Inc. (TSXV:DMA, OTCQB:DMCAF), announcedis undertaking a non-brokered private placement of up to 4,687,500 Units in the capital of the Company at an issue of $0.16 per Unit for gross proceeds of up to $750,000. The offer is subject to the approval of the TSX Venture exchange.

DiaMedica Inc. (TSXV:DMA, OTCQB:DMCAF), announcedis undertaking a non-brokered private placement of up to 4,687,500 Units in the capital of the Company at an issue of $0.16 per Unit for gross proceeds of up to $750,000. The offer is subject to the approval of the TSX Venture exchange.
According to the company’s press release:

Each Unit will consist of one common share in the capital of the Company (each a “Common Share”) and one-half Common Share purchase warrant (each whole warrant, a “Warrant”), with each Warrant entitling the holder thereof to acquire an additional Common Share at an exercise price of $0.25 per Common Share prior to the expiry date that is two years after the date of issuance. All of the Units issued in connection with the Offering will be subject to a restricted period that expires four months after the issuance date.

Click here to view the full press release. 

The Conversation (0)
×